Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TerrAscend Corp. (TSND.TO)
CAD0.81
-0.04 (-4.71%)
CA TSX Healthcare Drug Manufacturers - Specialty & Generic
Address
East Tower L5B 1M5
Mississauga, ON, CA
Mississauga, ON, CA
CEO
Ziad Ghanem
Website
terrascend.com
IPO
2017-05-03
ISIN CA88105E1088
Also trades on
Canadian Securities Exchange · TER.CN (CAD)
Other OTC · TRSSF (USD)
Other OTC · TSNDF (USD)
Toronto Stock Exchange · TSND.TO (CAD)
Description
TerrAscend Corp. operates as a comprehensive cannabis enterprise, engaging in the cultivation, processing, and distribution of cannabis products for both medical and regulated adult recreational markets across Canada and the United States. In addition to its core cannabis operations, the firm also develops and supplies hemp-derived wellness items to retail outlets and crafts specialty cannabis-infused edibles. It further expands its market presence by managing a network of retail dispensaries under The Apothecarium brand name in California, Pennsylvania, and New Jersey. The company's portfolio encompasses various integrated businesses and brands, including Gage Growth, Pinnacle, Ilera Healthcare, Valhalla Confections, State Flower, and Arise Bioscience Inc., among others. Established in 2017, TerrAscend maintains its corporate headquarters in Mississauga, Canada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CAD0.81
-0.04 (-4.71%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
306.9K
Beta
2.04
Float Shares
288.31M
Free Float %
93.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.12% | -7.92% | +6.90% | +19.23% | -2.11% | -6.06% | +86.00% | -57.34% | -93.22% | -23.14% | -23.14% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Hold
Price Targets & DCF
Current price
0.81
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-1.13
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-13.6% Q1'26: -9.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-3.6% Q1'26: +42.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+0.7% Q1'26: +11.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+17.1% ★ Q1'26: +17.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.6% ★ Q1'26: +8.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3.3% Q1'26: +5.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×5.65× Q1'26: 4.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.83M
est: 5.34M (+27.9%)
|
84.87M
est: 61.72M (+37.5%)
|
198.32M
est: 155.26M (+27.7%)
|
310.32M
est: 212.59M (+46.0%)
|
433.51M
est: 252.62M (+71.6%)
|
317.33M
est: 244.27M (+29.9%)
|
306.68M
est: 304.87M (+0.6%)
|
265.12M
est: 263.27M (+0.7%)
|
259.90M
255.91M – 263.06M
-1.3% YoY
|
275.60M
271.32M – 282.29M
+6.0% YoY
|
283.95M
279.56M – 289.18M
+3.0% YoY
|
302.96M
298.28M – 308.54M
+6.7% YoY
|
321.29M
316.33M – 327.21M
+6.0% YoY
|
| EBITDA |
-20.52M
est: -1.09M (-1,787.2%)
|
-149.97M
est: -12.58M (-1,092.5%)
|
-93.25M
est: -31.63M (-194.8%)
|
133.23M
est: -43.32M (+407.6%)
|
-431.22M
est: -51.47M (-737.8%)
|
-1.03M
est: -18.43M (+94.4%)
|
6.16M
est: -23.00M (+126.8%)
|
45.41M
est: -19.86M (+328.6%)
|
-19.61M
-19.85M – -19.31M
+1.3% YoY
|
-20.80M
-21.30M – -20.47M
-6.0% YoY
|
-21.43M
-21.82M – -21.09M
-3.0% YoY
|
-22.86M
-23.28M – -22.51M
-6.7% YoY
|
-24.24M
-24.69M – -23.87M
-6.0% YoY
|
| EBIT |
-19.89M
est: -1.41M (-1,306.2%)
|
-157.29M
est: -16.36M (-861.3%)
|
-109.82M
est: -41.16M (-166.8%)
|
87.16M
est: -56.36M (+254.7%)
|
-271.13M
est: -66.97M (-304.9%)
|
-23.73M
est: -29.33M (+19.1%)
|
-16.83M
est: -36.61M (+54.0%)
|
45.41M
est: -31.61M (+243.6%)
|
-31.21M
-31.59M – -30.73M
+1.3% YoY
|
-33.09M
-33.90M – -32.58M
-6.0% YoY
|
-34.10M
-34.73M – -33.57M
-3.0% YoY
|
-36.38M
-37.05M – -35.82M
-6.7% YoY
|
-38.58M
-39.29M – -37.99M
-6.0% YoY
|
| Net Income |
-22.03M
est: -47.14M (+53.3%)
|
-215.79M
est: -131.68M (-63.9%)
|
-155.12M
est: -54.15M (-186.5%)
|
4.97M
est: 7.31M (-32.0%)
|
-577.08M
est: -384.54M (-50.1%)
|
-91.10M
est: -61.01M (-49.3%)
|
-80.23M
est: -52.01M (-54.3%)
|
-87.74M
est: -21.40M (-310.0%)
|
-16.82M
-17.19M – -16.45M
+21.4% YoY
|
-9.59M
-9.80M – -9.38M
+43.0% YoY
|
-8.85M
-9.07M – -8.68M
+7.7% YoY
|
-5.90M
-6.04M – -5.78M
+33.3% YoY
|
-2.95M
-3.02M – -2.89M
+50.0% YoY
|
| SGA |
24.67M
est: 1.89M (+1,203.5%)
|
61.68M
est: 21.89M (+181.7%)
|
77.32M
est: 55.07M (+40.4%)
|
94.98M
est: 75.40M (+26.0%)
|
156.50M
est: 89.60M (+74.7%)
|
112.17M
est: 83.76M (+33.9%)
|
111.33M
est: 104.54M (+6.5%)
|
87.75M
est: 90.28M (-2.8%)
|
89.12M
87.75M – 90.21M
-1.3% YoY
|
94.50M
93.04M – 96.80M
+6.0% YoY
|
97.37M
95.87M – 99.16M
+3.0% YoY
|
103.89M
102.29M – 105.80M
+6.7% YoY
|
110.17M
108.47M – 112.20M
+6.0% YoY
|
| EPS |
-0.24
est: -0.16 (-48.4%)
|
-2.17
est: -0.45 (-380.4%)
|
-1.04
est: -0.19 (-459.9%)
|
0.03
est: 0.03 (+9.3%)
|
-2.36
est: -1.32 (-78.9%)
|
-0.33
est: -0.20 (-63.2%)
|
-0.28
est: -0.17 (-62.4%)
|
-0.29
est: -0.11 (-163.6%)
|
-0.06
-0.06 – -0.05
+49.3% YoY
|
-0.03
-0.03 – -0.03
+43.0% YoY
|
-0.03
-0.03 – -0.03
+7.5% YoY
|
-0.02
-0.02 – -0.02
+33.3% YoY
|
-0.01
-0.01 – -0.01
+50.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-15.64M
OE per share TTM
-0.05
Owner's Yield
-5.28%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
87.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 3 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 34.9K | 0.39% |
| 2 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 49.6K | 0.22% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 27.5K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
47.8K
Shares Outstanding
309.56M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ziad Ghanem | President & Chief Executive Officer | 1M | male |
| Eric Jackson | Chief Financial Officer | 946.0K | male |
| Lynn Gefen | Chief People Officer, Chief Legal Officer & Corporate Secretary | 930.2K | female |
| Jason Garrett Wild | Executive Chairman | 555.0K | male |
| David Wheeler | Senior Vice President & Chief Information Officer | — | male |
| Alisa Campbell | Senior Vice President of Corporate Finance & Accounting | — | female |
| Carretta | Senior Vice President of Marketing | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TSND.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
